CIK 0000899923
- Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 870494517
- Phone
- +1 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- 4 Grant or award Chief Technology Officer acquired 344 shares (grant or award)
- 4 Open-market sale Director sold 7,142 shares at $28.99 ($207,023)
- 4 Insider Changes in Ownership
- 4 Returned to the company Director returned 15,889 shares (to the company)
- 4 Open-market sale Chief Scientific Officer sold 19,360 shares at $31.97 ($618,949)
- 4 Open-market sale Chief Scientific Officer sold 40,000 shares at $31.47 ($1,258,800)
- 4 Open-market sale Lambert Nicole sold 6,649 shares at an average $27.01 ($179,586)
- 4 Insider Changes in Ownership
- 4 Grant or award Chief Growth Officer acquired 16,420 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief People Officer sold 58,000 shares at $30.00 ($1,740,000)
- 4 Grant or award President and CEO acquired 159,915 shares (grant or award)
- 4 Grant or award Chief People Officer acquired 13,326 shares (grant or award)
- 4 Grant or award E.V.P., General Counsel acquired 18,879 shares (grant or award)
- 4 Grant or award EVP Strategy and Innovation acquired 10,661 shares (grant or award)
- 4 Grant or award Chief Technology Officer acquired 13,326 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 19,347 shares (grant or award)
- 4 Grant or award President, Myriad Neuroscience acquired 15,441 shares (grant or award)
- 4 Grant or award President, Myriad Oncology, acquired 29,556 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 32,774 shares (grant or award)
Page 19 of 65 · 1,294 filings